Home  /  Resource Library  /  The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study

The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study

Study investigated the prognostic effect of body mass index in patients with hodgkin lymphoma treated with nivolumab